The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Johnson & Johnson has launched the Shockwave C2 Aero catheter, a fifth-generation device specifically engineered to treat complex calcified arterial lesions. The new device, developed by the company's Shockwave Medical unit, features enhanced flexibility and improved repositioning capabilities for surgical procedures. This launch aims to solidify the company's leadership in the intravascular lithotripsy (IVL) market and target high-growth medical technology segments.
This expansion follows J&J's acquisition of Shockwave Medical in a deal valued at approximately $13.1 billion in 2024, a strategic move to bolster its cardiovascular portfolio. The company competes in this space with major players such as Boston Scientific and Medtronic, as J&J seeks a larger share of the multi-billion dollar arterial calcification treatment market. Per market data, these innovations reflect continued growth in the company's MedTech unit, which has become a primary revenue driver.
Sign in to access this content
Sign InInvestors are monitoring JNJ stock, which stood at $152.40 (at close May 13, 2026), to evaluate the long-term returns of recent acquisitions. Looking at the economic calendar, the market awaits speeches from Fed officials, including Kashkari later today, for signals on financing costs affecting the healthcare sector. Technical support levels near $150 will be a key watch point for traders in upcoming sessions.